MindBio Begins Recruitment Of Participants For LSD-Microdosing Clinical Trial In Cancer Patients Experiencing Emotional Distress
Portfolio Pulse from Vuk Zdinjak
MindBio Therapeutics Corp. has begun recruiting participants for a phase 2 clinical trial using microdoses of LSD and psychotherapy to treat emotional distress in advanced stage cancer patients. The trial will involve 40 participants over a 6-week period. The company aims to address the high prevalence of depression, anxiety, and reduced quality of life in advanced-stage cancer patients.
July 25, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MindBio Therapeutics is starting a phase 2 clinical trial using LSD-microdosing to treat emotional distress in advanced stage cancer patients. This could potentially open a new treatment avenue and increase the company's market share in the cancer treatment sector.
The initiation of this clinical trial represents a potential expansion of MindBio's product portfolio and could open a new market segment for the company. If the trial is successful, it could lead to increased revenues and market share for MindBio. However, the outcome of the trial is uncertain and it is still in the early stages.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100